Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Springworks Therapeutics Inc
(NQ:
SWTX
)
41.48
-0.25 (-0.60%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Springworks Therapeutics Inc
< Previous
1
2
3
4
5
Next >
AbbVie, SpringWorks Join Forces To Conduct Multiple Myeloma Combo Therapy Trial
December 10, 2021
SpringWorks Therapeutics Inc (NASDAQ: SWTX) entered into a clinical trial collaboration agreement with AbbVie Inc (NYSE: ABBV) to evaluate SpringWorks...
Via
Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
December 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...
Via
Benzinga
Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial
June 28, 2021
Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision...
Via
Benzinga
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
June 28, 2021
From
Precision BioSciences, Inc.
Via
Business Wire
SpringWorks Therapeutics Reveals Updated Interim Mirdametinib Data In Rare Genetic Disorder
June 16, 2021
SpringWorks Therapeutics Inc (NASDAQ: SWTX) announced an update on the previously reported interim data from the first 20 adult patients enrolled in Phase 2b ReNeu...
Via
Benzinga
SpringWorks In-Licenses TEAD Inhibitor Portfolio For Solid Tumor Settings
May 06, 2021
SpringWorks Therapeutics Inc (NASDAQ: SWTX) has entered into an exclusive worldwide license agreement with Katholieke Universiteit Leuven (KU Leuven) and the...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.